Technology | November 19, 2012

Hologic’s best-in-class solutions for breast screening, intervention and treatment, osteoporosis risk assessment and extremity imaging highlight its commitment to putting Patients First

3D mammography (breast tomosynthesis) system

U.S. Food and Drug Administration (FDA) in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic’s 3D mammography technology is available in 46 states and 29 countries outside the U.S.

Hologic’s 3D mammography system placed first in the digital mammography category in the KLAS 2012 annual survey of healthcare executives and clinicians. 3D mammography was recently selected by AuntMinnie as the “hottest clinical procedure” of the year for the third year in a row. AuntMinnie is the largest and most comprehensive community Web site for medical imaging professionals worldwide. In October, the Cleveland Clinic picked 3D mammography as one of the Top 10 Medical Innovations for 2013 at the Clinic's 10th annual Medical Innovation Summit.

Fifteen of the clinical papers and over 50 of the workshops, seminars, poster sessions and scientific papers to be presented at the conference are on 3D mammography (breast tomosynthesis).  Clinical presentations cover the use of tomosynthesis in screening and diagnostic applications.

Hologic is once again offering RSNA meeting attendees sixteen 75-minute sessions with hands-on experience reading 3D breast tomosynthesis images in combination with conventional and synthesized 2D images. Brief lectures will provide an overview of the technologies prior to the hands-on sessions. Each program will be taught by a leading breast imaging radiologist.  Conference attendees can register to take a workshop through the RSNA meeting web site.

Some of Hologic’s other advances in breast tomosynthesis on display at the conference include its tomosynthesis biopsy option for use with the Affirm™ biopsy guidance system and its C-View™ synthesized 2D image option. The tomosynthesis biopsy option is CE marked and is pending FDA clearance. The C-View Synthesized 2D image option received CE marking in 2011 and received a favorable vote for approval from an FDA Advisory Panel in October 2012. 

For more information: www.hologic.com


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
Subscribe Now